From: Simulating the drug discovery pipeline: a Monte Carlo approach
Probability of achieving Hit to Lead milestone | 0.80 |
Probability of achieving Lead Optimization milestone | 0.75 |
Probability of achieving Preclinical Development milestone | 0.85 |
Percentage of follow-on Hit to Lead projects | 0.25 |
Percentage of chemistry-driven Hit to Lead projects | 0.5 |
Percentage of prioritized Lead Optimization projects | 0 |
Target no. Hit to Lead CHEMISTS (chemistry-driven) per team | 2 |
Target no. Hit to Lead BIOLOGISTS (chemistry-driven) per team | 3 |
Target no. Hit to Lead CHEMISTS (biology-driven) per team | 1 |
Target no. Hit to Lead BIOLOGISTS (biology-driven) per team | 3 |
Target no. Hit to Lead CHEMISTS (follow-on) per team | 2 |
Target no. Hit to Lead BIOLOGISTS (follow-on) per team | 1 |
Target no. Lead Optimization CHEMISTS per team | 4 |
Target no. Lead Optimization BIOLOGISTS per team | 4 |
No. simultaneous Lead Optimization projects supported by DMPK | 0 |
Percent impact on timeline by DMPK support | 0.1 |
Target cycle time (months) to achieve Lead Optimization | 18 |
Target cycle time (months) to achieve Preclinical Development | 24 |
Group size at 75% FTE efficiency | 20 |
Group size at 50% FTE efficiency | 40 |